Cardio Diagnostics Holdings Inc (NASDAQ:CDIO) — Market Cap & Net Worth
Market Cap & Net Worth: Cardio Diagnostics Holdings Inc (CDIO)
Cardio Diagnostics Holdings Inc (NASDAQ:CDIO) has a market capitalization of $5.42 Million ($5.42 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28430 globally and #5773 in its home market, demonstrating a 2.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cardio Diagnostics Holdings Inc's stock price $1.98 by its total outstanding shares 2959469 (2.96 Million). Review Cardio Diagnostics Holdings Inc (CDIO) total liabilities to assess the company's total debt and financial obligations.
Cardio Diagnostics Holdings Inc Market Cap History: 2022 to 2026
Cardio Diagnostics Holdings Inc's market capitalization history from 2022 to 2026. Data shows change from $3.14 Million to $5.86 Million (-30.37% CAGR).
Index Memberships
Cardio Diagnostics Holdings Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #833 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2660 of 3165 |
Weight: Cardio Diagnostics Holdings Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cardio Diagnostics Holdings Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cardio Diagnostics Holdings Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
540.99x
Cardio Diagnostics Holdings Inc's market cap is 540.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $3.14 Million | $950.00 | -$4.66 Million | 3302.14x | N/A |
| 2023 | $7.37 Million | $17.07K | -$8.38 Million | 431.82x | N/A |
| 2024 | $2.71 Million | $34.89K | -$8.38 Million | 77.78x | N/A |
| 2025 | $8.02 Million | $14.82K | -$6.50 Million | 540.99x | N/A |
Competitor Companies of CDIO by Market Capitalization
Companies near Cardio Diagnostics Holdings Inc in the global market cap rankings as of June 18, 2026.
Key companies related to Cardio Diagnostics Holdings Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Cardio Diagnostics Holdings Inc Historical Marketcap From 2022 to 2026
Between 2022 and today, Cardio Diagnostics Holdings Inc's market cap moved from $3.14 Million to $ 5.86 Million, with a yearly change of -30.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $5.86 Million | -26.94% |
| 2025 | $8.02 Million | +195.53% |
| 2024 | $2.71 Million | -63.17% |
| 2023 | $7.37 Million | +134.91% |
| 2022 | $3.14 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Cardio Diagnostics Holdings Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.42 Million USD |
| MoneyControl | $5.42 Million USD |
| MarketWatch | $5.42 Million USD |
| marketcap.company | $5.42 Million USD |
| Reuters | $5.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cardio Diagnostics Holdings Inc
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart dise… Read more